Altimmune Inc ALT.OQ ALT.O is expected to show a fall in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The Gaithersburg Maryland-based company is expected to report a 75.0% decrease in revenue to $1.25 thousand from $5 thousand a year ago, according to the mean estimate from 8 analysts, based on LSEG data.
LSEG's mean analyst estimate for Altimmune Inc is for a loss of 28 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Altimmune Inc is $18.00, about 78% above its last closing price of $3.96
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.33 | -0.32 | -0.27 | Beat | 16.4 |
Mar. 31 2025 | -0.37 | -0.36 | -0.26 | Beat | 28.4 |
Dec. 31 2024 | -0.34 | -0.33 | -0.33 | Met | -0.8 |
Sep. 30 2024 | -0.38 | -0.35 | -0.32 | Beat | 9.6 |
Jun. 30 2024 | -0.34 | -0.34 | -0.35 | Missed | -2.6 |
Mar. 31 2024 | -0.36 | -0.37 | -0.34 | Beat | 7.4 |
Dec. 31 2023 | -0.56 | -0.43 | -0.33 | Beat | 23.9 |
Sep. 30 2023 | -0.41 | -0.42 | -0.39 | Beat | 8.1 |
This summary was machine generated November 4 at 14:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)